The global market for high content screening is currently witnessing the emergence of several notable trends from the product, application, and industry perspective. Growing concerns of pharmaceutical companies towards toxicity studies is shifting focus on secondary cell screening.
Further, biotechnology and pharmaceutical companies are deploying high content screening solutions for effective risk assessment of critical illnesses to facilitate efficient drug discovery. Manufacturers in the high content screening market are offering advanced instruments to facilitate various lab services.
Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/12931
- Becton, Dickinson and Company
- Thermo Fisher Scientific Inc.
- GE Healthcare
- Olympus Corporation
- PerkinElmer Inc.
- Merck Millipore Corporation
- Danaher Corporation (Molecular Devices)
- Yokogawa Electric Corporation
- Sysmex Corporation
These factors are currently trending the global market for high content screening, as elucidated in a new research publication by Persistence Market Research.
According to the forecast presented in the report, the global high content screening market is projected to register a CAGR of 5.0% during the period 2018 to 2026. Global market revenue is estimated to stand at US$ 1,379.7 Mn by 2018 end, and this is expected to increase to US$ 2,039.9 Mn by 2026.
Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/12931
The last few years have witnessed the development of automated systems for the analysis of cell separation and cellular scalability. An increasing demand for effective therapeutic cell purification protocols is being observed, leading to a surge in adoption of high content screening systems in the coming years.
Another factor that is expected to bode well for the high content screening market is the development of advanced software with instrumentation that facilitates both qualitative and statistical image analysis.
High content screening systems help pharmaceutical and biotechnology companies extract useful multiplex information from assays, thereby leading to a surge in demand for advanced high content screening systems from the pharmaceutical industry.
Advancements in the software and services underpinning high content screening solutions are also being observed in the global market. Being a highly complex software suite, companies in the high content screening market are creating better user-friendly and cloud-based platforms to help address the requirements of end users.
Companies are also launching integrated solutions that can meet the varying demands from biological and pharmaceutical companies for advanced cell analysis and cell culture equipment.
Companies in the High Content Screening Market Entering Into Strategic Partnerships and Setting Up Manufacturing Hubs at Diverse Locations to Cement Global Market Footing
The global market for high content screening is expected to witness several strategic alliances among key players in the near future. One of the main objectives of such collaborations is to be able to offer high content screening instruments to end users on a large scale in the global market.
Companies are also looking at the lucrative markets in India and China to expand their geographical presence, owing to the increasing number of biotechnology and pharmaceutical companies and rising investments in healthcare research and development for new drug discovery in these countries.
Companies operating in the global high content screening market are also setting up manufacturing facilities across different geographical locations, with a view to cater to the rising local demand and augment their overall market presence across the globe.
Access Full Report @ https://www.persistencemarketresearch.com/checkout/12931
New product launches is another key strategy being adopted by companies in the high content screening market. Being a highly consolidated market, key players offering high content screening solutions are focused on introducing new product lines including consumables, instruments, services, and software; with an objective to sustain their brand name and restrict the entry of new players in the global high content screening market.
A heavy pumping in of R&D investments to facilitate new product launches especially catering to the requirements of pharmaceutical companies is another trend being observed in the global market for high content screening. Companies are focusing on developing advanced reagents that are a crucial component of the cellular screening process and are also actively engaged in the marketing and distribution of high content screening solutions in the global market.